UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **May 2, 2016**

FLAMEL TECHNOLOGIES S.A.

(Exact name of registrant as specified in its charter)

Republic of France	**000-28508**	**98-0639540**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Parc Club du Moulin à Vent **33, avenue du Docteur Georges Levy** **69200 Vénissieux France** (Address of Principal Executive Offices)	**Not Applicable** (Zip Code)

Registrant's telephone number, including area code: **011 +33 472 78 34 34**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On May 4, 2016, Flamel Technologies S.A. (the "Company") intends to make a presentation at Deutsche Bank's 41st Annual Health Care Conference in Boston, Massachusetts. A copy of the Company's complete slide presentation to be used at the Conference is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company's presentation will be webcast live and can be accessed by visiting the Investor section of the Company's website at http://www.flamel.com/investors. A replay of the presentation, together with the complete slide presentation, will also be available and archived for at least 30 days on the website following the event.

The information responsive to Item 7.01 of this Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as may be expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On May 2, 2016, the Company issued a press release, a copy of which is furnished as Exhibit 99.2 to this current report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1		Form of Slide Presentation of Flamel Technologies S.A. as of May 4, 2016.
99.2		Press release of Flamel Technologies S.A. dated as of May 2, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

FLAMEL TECHNOLOGIES S.A.

By: /s/ Phillandas T. Thompson
Phillandas T. Thompson
Senior Vice President, General Counsel and Corporate Secretary

Date: May 4, 2016

Exhibit Index

99.1		Form of Slide Presentation of Flamel Technologies S.A. as of May 4, 2016.
99.2		Press release of Flamel Technologies S.A. dated as of May 2, 2016.


FLAMEL
technologies

Forward Looking Statements

This presentation may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "assume," "believe," "expect," "estimate," "plan," "will," "may," and the negative of these and similar expressions generally identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond Flamel's control and could cause actual results to differ materially from the results contemplated in such forward-looking statements. These risks, uncertainties and contingencies include the risks relating to: our dependence on a small number of products and customers for the majority of our revenues; the possibility that our Bloxiverz® and Vazculep® products, which are not patent protected, could face substantial competition resulting in a loss of market share or forcing us to reduce the prices we charge for those products; the possibility that we could fail to successfully complete the research and development for the two pipeline products we are evaluating for potential application to the FDA pursuant to our "unapproved-to-approved" strategy, or that competitors could complete the development of such products and apply for FDA approval of such products before us; our dependence on the performance of third parties in partnerships or strategic alliances for the commercialization of some of our products; the possibility that our products may not reach the commercial market or gain market acceptance; our need to invest substantial sums in research and development in order to remain competitive; our dependence on certain single providers for development of several of our drug delivery platforms and products; our dependence on a limited number of suppliers to manufacture our products and to deliver certain raw materials used in our products; the possibility that our competitors may develop and market technologies or products that are more effective or safer than ours, or obtain regulatory approval and market such technologies or products before we do; the challenges in protecting the intellectual property underlying our drug delivery platforms and other products; our dependence on key personnel to execute our business plan; the amount of additional costs we will incur to comply with U.S. securities laws as a result of our ceasing to qualify as a foreign private issuer; and the other risks, uncertainties and contingencies described in the Company's filings with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2015, all of which filings are also available on the Company's website. Flamel undertakes no obligation to update its forward-looking statements as a result of new information, future events or otherwise, except as required by law.

Investment Highlights

- Strong financial position – profitable with strong cash flow & balance sheet
  - $173.2 million in product revenues in 2015
  - $84.3 million cash flow from operations generated in 2015; no debt
- Initiating Phase III pivotal trial using Micropump® sodium oxybate in 2016
  - Current market size in excess of $900 million
- Expanding commercial product portfolio:
  - 7 FDA approved products from Éclat Portfolio & FSC Pediatrics acquisition
- Robust pipeline with strong IP protection – ongoing projects include:
  - LiquiTime® for OTC and Rx
  - Trigger Lock™ hydromorphone
  - Medusa™ exenatide

Mission: To build a diversified specialty pharmaceutical company that controls 100% of its drug development and future

Flamel Technologies Transformed



Transition from an unprofitable stand alone drug delivery company to a diversified specialty pharma company that is profitable and cash flow positive

2016 Expectations

- Commence patient registration & dosing for pivotal study of Micropump® sodium oxybate by mid year
- Complete cross border merger to Ireland
- Launch Akovaz™ (Approved on April 29, 2016)
- Integrate & market newly acquired FSC Pediatrics' products
- Begin licensing discussions for Trigger Lock™ platform
- Report data from Phase 1b study with Medusa™ exenatide in patients
- Begin development of UMD #4 [1]

Achieve total product sales of $110-130 million

[1] UMD is Flamel's Unapproved Marketed Drugs Strategy, which takes unapproved drugs through the FDA approval process. These products are not protected by IP and are subject to generic filers.

Current Pipeline

Drug/ Technology	Indication	Proof of Concept	Pilot	Pivotal	Under Review	Approved
UMD #4	Undisclosed					
Sodium oxybate/ Micropump®	Narcolepsy					
Ibuprofen / LiquiTime®	Pain / Fever					
Guaifenesin / LiquiTime®	Respiratory					
Hydromorphone / Trigger Lock™	Pain					
Exenatide/Medusa™	Diabetes					

Micropump® Sodium Oxybate (FT218)

FT218 Overview

- Extended release oral solid formulation of sodium oxybate using Micropump®
- Studied in 40 healthy volunteers across 2 studies
- **Standard of care:** Jazz's Xyrem® dosed 2x nightly
  - **Improved formulation needed:** Micropump® profile consistent with target of 1x dose before bedtime
- Announced submission of SPA and IND on March 31, 2016
- **Next step:** Initiate patient registration and begin pivotal study

Market Opportunity

- Jazz's Xyrem® FY 2015 sales **were $955.2 million***
- >~178,000 narcoleptic patients in the U.S.*
- Jazz reports **< 13,000 patients on treatment***
- Limited competition to date

* *GlobalData & JAZZ's 4Q'15 earnings call*

Trigger Lock™ Hydromorphone (FT227)

FT227 Overview

- Abuse-deterrent, extended-release, oral hydromorphone product for treatment of pain – technology is applicable to all opioids
- Positive results from two pilot PK studies in healthy volunteers announced in June 2015
- **Next step:** Continue dialogue with FDA regarding pivotal study in 1H 2016; begin partnering discussions

Market Opportunity

- U.S. market for prescription painkillers (all forms) in 2015: **$6.5 billion** [1]
  - OxyContin® (extended-release oxycodone, Purdue): **$2.1 billion** [1]
  - ER hydromorphone (Exalgo® & generics) **$138 million** [1]
- Opioid prescriptions grew from ~76 million in 1991 to ~207 million in 2013 [2]
- ~2.1 million people suffered from substance use disorders related to prescription opioids[2]

[1] IMS data [2] "America's Addiction to Opioids: Heroin and Prescription Drug Abuse" (National Institute on Drug Abuse, May 14, 2014)

Medusa™ Exenatide (FT228)

FT228 Overview

- Subcutaneous injection formulation of exenatide, a GLP-1 (glucagon-like peptide – 1) for treatment of Type 2 diabetes
- Interim Phase I human clinical data reported in December 2015
- PK profile compatible with a release over one week in humans
- **Next step:** Complete Phase 1b study in 1H 2016

Market Opportunity

- Market opportunity: GLP-1 products recorded **$3.9 billion* of sales:**
  - **$2.5 million** for Victoza® (once a day liraglutide, Novo Nordisk)
  - **$736 million** for Bydureon® (once-a-week exenatide, AstraZeneca)
  - **$319 million** for Byetta® (twice-a-day exenatide, AstraZeneca)

LiquiTime® Platform Overview

Overview

- Extended release liquid oral suspension for more convenient and improved dosing with a focus on pediatric and geriatric markets
- **Exclusive U.S. rights licensed to Perrigo for the OTC drug market: development ongoing**
- Flexible capability allows for the combination of multiple active ingredients

Market Opportunity

- Cough and cold U.S. market is estimated at **$6.5 billion annually**[1]
- **Potential for liquid prescription products is largely untapped**

[1] *IMS – U.S. sales*

Marketed Products

Éclat Portfolio Products

Bloxiverz® (neostigmine methylsulfate injection)

- Indication: Reverses neuromuscular blockades used in surgical procedures
- 1 of 3 approved versions; ~ 4 million vials sold annually in the U.S.*

Vazculep® (phenylephrine hydrochloride injection)

- Indication: Treatment of hypotension resulting primarily from vasodilation in the setting of anesthesia
- Form: 1 mL single use vials, 5 mL and 10 mL
  - 1mL vial – **5.7** million 5mL vial – **1.2** M 10mL vial – **0.2** million

Akovaz™
(Ephedrine Sulfate Injection, USP)
(50 mg/mL)

Akovaz™ (ephedrine sulfate injection)

- Indication: Treatment of hypotension clinically important hypotension occurring in the setting of anesthesia
- ~ 5 million vials sold annually in the U.S.

FLAMEL technologies

* *IMS data*

FSC Acquisition

FSC pediatrics

In line with Company's strategy to become a fully integrated global specialty pharmaceutical company

- Commercial stage specialty pharmaceuticals company headquartered Charlotte, NC
- Provides 4 commercial stage assets to be marketed by 45 person salesforce
- Positions Flamel as a more attractive business partner for potential pediatric and geriatric assets
- Fixed acquisition price totals $20.25 million paid over a five year period
  - $1 million annually for five years
  - Final payment in January 2021 of $15.0 million
- Expected 2016 revenues to approximate $10-$15 million

FSC Products

Karbinal ER
(carbinoxamine maleate) extended-release oral suspension / 4mg/5mL

- Indication: Perennial allergic rhinitis in children 2 years of age and older
- Patent protection through March 2029
- Rx antihistamine market size in U.S. ~ $11M

CEFACLOR
For Oral Suspension, USP
125 mg/5 mL • 250 mg/5 mL • 375 mg/5 mL

- Indication: 2nd generation Cephalosporin covering a variety of common pathogens
- For children as young as 1 year
- U.S. Market for Cephalosporin ~ $300M

AcipHex® Sprinkle™
(rabeprazole sodium)

- Indication: Treatment of GERD in pediatric patients aged 1-11 years
- Proton Pump Inhibitor (PPI)
- Market size in U.S. ~ $110M

Oflexichamber®
Anti-static Valved Collapsible Holding Chamber Rx Only

- Indication: Collapsible asthma spacer for use with metered dose inhalers (MDIs)
- Patent protection through March 2028
- Market size in U.S. ~ $50M

Strong Intellectual Property

	Patent Protection Through..	
Platform	**US**	**Europe**
Micropump®	July 2027	July 2023
LiquiTime®	September 2025	April 2023
Trigger Lock™	April 2027	May 2026 (pending)
Medusa™	June 2031	June 2027 (pending)

Product	**US**
Karbinal™ ER	March 2029
AcipHex® Sprinkle™	September 2016
Flexichamber®	March 2028

Seasoned Senior Management

Name	Title	Experience
Michael S. Anderson	**Chief Executive Officer**	40+ years Pharma
Sandy Hatten	**Senior Vice President, Quality and Regulatory Affairs**	30+ years Pharma
Phillandas T. Thompson, J.D., M.B.A.	**Senior Vice President, General Counsel**	16+ years Legal
Mike Kanan	**Senior Vice President and Chief Financial Officer**	30+ years Financial
Gregory J. Davis	**Vice President, Corporate and Business Development**	20+ years Pharma
David Monteith, Ph.D.	**Vice President, Research and Development**	25+ years Pharma
Dhiren D'Silva	**Vice President of Irish and European Operations**	19+ years Business

Key Financial Metrics (Unaudited)

In Millions USD, Except Per Share Data:

Income Statement Metrics	Twelve months ended December 31,	
	2015	2014
Revenue	$ 173.2	$14.8
COGS	(10.9)	(3.4)
R&D	(25.6)	(17.3)
SG&A	(21.7)	(15.7)
Acquisition Earn-Out Payments/Accruals	(32.2)	(1.7)
Adj Op. Profit (Loss) *	82.8	(23.3)
Adj. Net Income (Loss) *	43.1	(24.6)
Adjusted Diluted EPS *	0.99	(0.68)

Balance Sheet Metrics	At December 31,	
	2015	2014
Cash & Marketable Securities	$ 144.8	$92.8
Goodwill & Intangible Assets	34.3	46.9
Long-term Contingent Consideration Liability	122.7	114.8

Cash Flow Metrics	Twelve months ended December 31,	
	2015	2014
Free Cash Flow *	$ 58.1	($13.7)

* = Non-GAAP. See Reconciliation of Non GAAP to GAAP in Appendix

Flamel Technologies Transformed

- **Strong financial condition - profitable with strong cash flow and balance sheet**
- **Seven FDA approved products**
- **Experienced management team**
- **Robust pipeline with extensive IP protection**

Mission: To build a diversified specialty pharmaceutical company that controls 100% of its drug development and future

Appendix

Reconciliation of Non GAAP to GAAP Results

		Operating Income (Loss)		Net Income (Loss)		Diluted Earnings (Loss) per share	
		2015	2014	2015	2014	2015	2014
Reported		**$ 71.4**	$ (93.9)	**$ 40.7**	$ (84.9)	**$ 0.93**	$ (2.34)
Exclude:	Contingent consideration - Acquisition-related fair value remeasurements - Inc./(Dec.)	**31.0**	57.5	**31.0**	57.5	**0.71**	1.59
	Contingent consideration - Financing-related fair value remeasurements - Inc./(Dec.)	*n/a*	*n/a*	**4.8**	3.5	**0.11**	0.10
	Intangible asset amortization	**12.6**	11.8	**12.6**	11.8	**0.29**	0.32
	Unrealized foreign exchange (gain)/loss	*n/a*	*n/a*	**(6.8)**	(11.7)	**(0.15)**	(0.32)
	Loss on early repayment of related party acquisition-related note	-	3.0	-	3.0	-	0.08
	Loss on early repayment of related party facility agreement notes	*n/a*	*n/a*	-	4.7	-	0.13
	Net income from discontinued operations	*n/a*	*n/a*	-	(4.0)	-	(0.11)
Include:	Contingent consideration - Acquisition-related paid/accrued	**(32.2)**	(1.7)	**(32.2)**	(1.7)	**(0.74)**	(0.05)
	Contingent consideration - Financing-related paid/accrued	*n/a*	*n/a*	**(4.4)**	(0.2)	**(0.10)**	(0.01)
Income tax expense (benefit) related to all above adjustments		*n/a*	*n/a*	**(2.6)**	(2.6)	**(0.06)**	(0.07)
Total adjustments		**11.4**	70.6	**2.4**	60.3	**0.06**	1.66
Adjusted		**$ 82.8**	$ (23.3)	**$ 43.1**	$ (24.6)	**$ 0.99**	$ (0.68)

Free Cash Flow:		2015	2014
Net cash provided by (used in) operating activities		**$ 84.3**	$ (10.6)
Less:	Purchases of property and equipment	**(1.6)**	(1.7)
	Earn-out payments for related party acquisition-related contingent consideration	**(24.6)**	(1.4)
Free Cash Flow		**$ 58.1**	$ (13.7)

Diversified and Proven Drug Delivery Platforms

- Outstanding drug delivery platforms to tackle key challenges in the formulation, in **various dosage forms** (e.g. capsules, tablets, sachets or **oral** liquid suspensions; or **injectable** for subcutaneous administration) of a broad range of drugs (already-marketed, off-patent or novel)



Micropump® Platform at a Glance

- Extended/delayed-release of drugs in the GI tract
- Precise pharmacokinetics of single or combination of drugs in various formats
- Numerous Micropump®-based products successfully tested in human clinical trials



Micropump Microparticles for Controlled/Modified Release



- Microparticles are dispersed in the stomach and pass into the small intestine, after which each microparticle releases the drug at an adjustable rate and over an extended period of time (up to 24 hours)
- Drug released at an adjustable rate controlled and/or delayed
- Micropump® microparticles can be used separately or together to provide highly specialized delivery profiles

LiquiTime® Platform at a Glance

LiquiTime® is a novel, proprietary and innovative delivery platform allowing the stable **Liquid** and **controlled release** formulation of one or several combined drugs over **Time**

LiquiTime® meets challenges faced in the treatment of pediatric and geriatric patients and patient populations who have difficulty swallowing tablets or capsules, and may provide better patient compliance



This graph illustrates the different near zero-order release profiles which can be tailored for the same drug

LiquiTime's versatility allows **once- or twice-daily liquid formulations** of a wide variety of drugs

LiquiTime® for Extended-Release Liquid Suspension

Liquid suspension contains small coated drug microparticles
A dose typically contains 5,000 to 50,000 particles

ER microparticles are suspended in the liquid medium

Granules
drug granulate or layered neutral core

Coating
- controls diffusion
- keeps its integrity
- offers good resistance to stress

Each microparticle is individually coated and behaves as an independent micro reservoir

Trigger Lock™ Platform at a Glance

Trigger Lock™ is a proprietary and innovative delivery platform that enables the **controlled release of narcotic and opioid analgesics while deterring their abuse**

Trigger Lock™ successfully addresses the issues of narcotic/opioid analgesics tampering:

- ✓ The sustained release Micropump®-based microparticles are resistant to crushing: each microparticle retains its polymer coating which is virtually impervious to further crushing
- ✓ Trigger Lock™ resists extraction attempts (even in boiling liquids) with beverages (alcoholic or not) preventing injection
- ✓ Trigger Lock™ preserves the bioavailability of the narcotic/opioid analgesics
- ✓ Trigger Lock™ is compatible with different dosage forms (capsules, tablets)

Trigger Lock™ SR Microparticles for Abuse Resistance

1. **Drug loaded Micropump® microparticles**
   Sustained Release (SR) microparticles which are resistant to crushing
2. **Viscosifying ingredient(s)**
   To prevent abuse by injection after extraction in a small volume of solvent
3. **Quenching ingredient(s)**
   To prevent extraction in large volumes of liquid

- **Each microparticle retains its polymer coating which is virtually impervious to further crushing**

Medusa™ Platform at a Glance



Medusa™ Depot for Injection

- Made of polyglutamic acid and Vitamin E
- Amphiphilic and spontaneously forms stable nanoparticles in water
- Complexes are stable over a wide range of pH



Formulation by simple mixing in water
Non-covalent association
(reversible hydrophobic and/or electrostatic interaction)
of the drug with Medusa™ nanoparticles

In vivo depot formation

Sustained release of the unmodified drug over 1 to 7 days

In Vitro

In Vivo

Specialty Pharmaceutical Company with Proprietary Drug Delivery Platforms Focused on Improved or Cost-Effective Products

Headquarters

33 avenue du Dr. Georges Levy
69200 Vénissieux (Lyon)
France

Corporate Contact

Phone: +33 472 783 434
Fax: +33 472 783 435
E-mail: licensing@flamel.com

U.S. Commercial Operations

16640 Chesterfield Grove Road, Suite 200
Chesterfield, MO
Phone: 636 449 1830
Fax: 636 449 1850

Exhibit 99.2

Flamel Technologies to Report First Quarter 2016 Results

Lyon, France – May 2, 2016 - Flamel Technologies (NASDAQ: FLML) today announced that the Company will report its financial results for the first quarter ended March 31, 2016 on Monday, May 9, 2016, before the market open. A conference call to discuss these results has been scheduled for Monday, May 9, 2016 at 10:00 a.m. ET. A question and answer period will follow management's prepared remarks.

To participate in the conference call, investors are invited to dial 800-753-0420 (U.S. and Canada) or 913-312-0645 (international). The conference ID number is 3821495. A live audio webcast can be accessed by visiting the Investor section of the Company's website at http://www.flamel.com/investors. A replay of the webcast will be archived on Flamel's website for 90 days following the event.

About Flamel Technologies:
Flamel Technologies SA (NASDAQ: FLML) is a specialty pharmaceutical company utilizing its core competencies in formulation development and drug delivery to develop safer and more efficacious pharmaceutical products, addressing unmet medical needs and/or reducing overall healthcare costs. Flamel currently markets two previously Unapproved Marketed Drugs ("UMDs") in the United States, Bloxiverz® (neostigmine methylsulfate injection) and Vazculep® (phenylephrine hydrochloride injection). The Company also develops products utilizing its proprietary drug delivery platforms, Micropump® (oral sustained release microparticles platform), along with its tangent technologies, LiquiTime® (a Micropump-derivative platform for liquid oral products) and Trigger Lock™ (a Micropump-derivative platform for abuse-resistant opioids). Additionally, the Company has developed a long acting injectable platform, Medusa™, a hydrogel depot technology. Current applications of Flamel's drug delivery products include sodium oxybate (Micropump®), extended-release of liquid medicines such as ibuprofen and guaifenesin (LiquiTime®, through a license arrangement with Elan Pharma International Limited for the U.S. Over-the-Counter market) and a current study of the delivery of exenatide utilizing the Medusa™ technology. In February 2016, Flamel acquired FSC Pediatrics, a Charlotte, North Carolina-based company that markets three pediatric pharmaceutical products - Cefaclor for oral suspension, indicated for infection, Karbinal™ ER, indicated for allergic rhinitis and AcipHex® Sprinkle™ (rabeprazole sodium) indicated for the treatment of gastroesophageal disease (GERD). FSC also received 510(k) clearance from the FDA in October 2014 for Flexichamber™, a collapsible holding chamber for used in the administration of aerosolized medication using pressurized Metered Dose Inhalers (pMDIs) for the treatment of asthma. The Company is headquartered in Lyon, France and has operations in Dublin, Ireland and in the USA in both St. Louis, Missouri and Charlotte, North Carolina. Additional information may be found at www.flamel.com.

Safe Harbor: *This release may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "assume," "believe," "expect," "estimate," "plan," "will," "may," and the negative of these and similar expressions generally identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond Flamel's control and could cause actual results to differ materially from the results contemplated in such forward-looking statements. These risks, uncertainties and contingencies include the risks relating to: our dependence on a small number of products and customers for the majority of our revenues; the possibility that our Bloxiverz® and Vazculep® products, which are not patent protected, could face substantial competition resulting in a loss of market share or forcing us to reduce the prices we charge for those products; the possibility that we could fail to successfully complete the research and development for the two pipeline products we are evaluating for potential application to the FDA pursuant to our "unapproved-to-approved" strategy, or that competitors could complete the development of such products and apply for FDA approval of such products before us; our dependence on the performance of third parties in partnerships or strategic alliances for the commercialization of some of our products; the possibility that our products may not reach the commercial market or gain market acceptance; our need to invest substantial sums in research and development in order to remain competitive; our dependence on certain single providers for development of several of our drug delivery platforms and products; our dependence on a limited number of suppliers to manufacture our products and to deliver certain raw materials used in our products; the possibility that our competitors may develop and market technologies or products that are more effective or safer than ours, or obtain regulatory approval and market such technologies or products before we do; the challenges in protecting the intellectual property underlying our drug delivery platforms and other products; our dependence on key personnel to execute our business plan; the amount of additional costs we will incur to comply with U.S. securities laws as a result of our ceasing to qualify as a foreign private issuer; and the other risks, uncertainties and contingencies described in the Company's filings with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2015, all of which filings are also available on the Company's website. Flamel undertakes no obligation to update its forward-looking statements as a result of new information, future events or otherwise, except as required by law.*

****

Contacts: **Michael S. Anderson**
Chief Executive Officer
Phone: (636) 449-1830
E-mail: anderson@flamel.com

Michael F. Kanan
Chief Financial Officer
Phone: (636) 449-1844
E-mail: kanan@flamel.com

Lauren Stival
Sr. Director, Investor Relations and Corporate Communications
Phone: (636) 449-5866
Email: stival@flamel.com

Stephanie Carrington
ICR Inc.
Phone: (646) 277-1282
Email: stephanie.carrington@icrinc.com